Hydroxyapatite cement cranioplasty in the setting of simultaneous translabyrinthine resection of cerebellopontine angle tumors and cochlear implantation.

Autor:	Conway RM; Department of Otolaryngology-Head & Neck Surgery, Ascension Macomb-Oakland Hospital, Madison Heights., Tu NC; Michigan Ear Institute, Farmington Hills; and., Sioshansi PC; Michigan Ear Institute, Farmington Hills; and., Bojrab DI 2nd; Michigan Ear Institute, Farmington Hills; and., Jacob JT; Michigan Head & Spine Institute, Southfield, Michigan., Babu SC; Michigan Ear Institute, Farmington Hills; and.
Jazyk:	angličtina
Zdroj:	Neurosurgical focus: Video [Neurosurg Focus Video] 2021 Oct 01; Vol. 5 (2), pp. V15. Date of Electronic Publication: 2021 Oct 01 (Print Publication: 2021).
DOI:	10.3171/2021.7.FOCVID211
Abstrakt:	Cochlear implantation (CI) has become an option for the treatment of hearing loss after translabyrinthine resection of vestibular schwannomas. The surgical video presents the case of a 67-year-old male who had translabyrinthine resection of vestibular schwannoma with simultaneous CI and closure with a hydroxyapatite (HA) cement cranioplasty. HA cement cranioplasty can be utilized in place of abdominal fat graft for the closure of translabyrinthine approaches with similar efficacy and complication profile. To the authors' knowledge, this is the first reported case of a simultaneous CI and translabyrinthine resection of vestibular schwannoma with HA cement cranioplasty. The video can be found here: https://stream.cadmore.media/r10.3171/2021.7.FOCVID211. Competing Interests: Disclosures Dr. Babu reports honorarium from Acclarent/Johnson & Johnson and research grants from Cochlear Corporation and Oticon Medical. Some patients who did not obtain insurance approval for simultaneous cochlear implantation received the implant provided by the cochlear implant company through research support. No financial payment was made to the authors for any part of this study.Dr. Babu reports honorarium from Acclarent/Johnson & Johnson and research grants from Cochlear Corporation and Oticon Medical. Some patients who did not obtain insurance approval for simultaneous cochlear implantation received the implant provided by the cochlear implant company through research support. No financial payment was made to the authors for any part of this study. (© 2021, The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu